Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
MitoRx Therapeutics logo — Developing new treatments to restore healthy mitochondrial m...

MitoRx Therapeutics

Developing new treatments to restore healthy mitochondrial metabolism in patients living with high-risk obesity.

Founded 2021 United Kingdom Oxford, United Kingdom 17 employees Seed Total: $4.00M Biotechnology, Health and Wellness

General Information

Company Name MitoRx Therapeutics
Founded Year 2021
Location United Kingdom Oxford, United Kingdom +1
Employees 17
Industries Biotechnology, Health and Wellness
Funding Stage Seed
Social

Get notified when MitoRx Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About MitoRx Therapeutics

MitoRx Therapeutics is a pre-clinical stage rare disease biotech company founded in 2016 with the mission to arrest the progression of degenerative diseases driven by mitochondrial dysfunction. Their focus lies on neuromuscular disease, metabolic disease, and neurodegenerative disease. The company, headquartered in the United Kingdom, aims to become the leading global developer of medicines in this field. Their latest milestone includes a significant achievement with a £4.00M Seed Round investment at 13 December 2023, which was led by notable investors such as Oxford Technology Management, UK Innovation & Science Seed Fund, The Fink Family Office, Science Angel Syndicate, Wren Capital LLP, and LongevityTech.fund. MitoRx Therapeutics' dedication to addressing critical health challenges through innovative biotechnology positions the company as a potential game-changer in the biopharmaceutical industry.

Taxonomy: biotech, rare disease, neuromuscular disease, metabolic disease, neurodegenerative disease, mitochondrial dysfunction, drug discovery, mitochondrial disease, Duchenne, mitochondria, muscular dystrophy, pre-clinical stage, therapeutics, novel, first-in-class

Services & Products

development of obesity treatments
restoration of mitochondrial metabolism
therapy for insulin resistance

Target Customers

individuals with high-risk obesity patients with metabolic disorders healthcare providers focusing on obesity

Funding Rounds & Investors (3)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round •••••• 6
Investor Investor Investor Investor Investor
•••• •••• 		13 Dec 2023
Seed Round •••••• 4
Investor Investor Investor
•••• •••• 		25 Apr 2022
Funding Round •••••• - 01 Mar 2019

MitoRx Therapeutics Alternatives & Competitors

MitoRx Therapeutics vs
Luciole Pharmaceuticals, Inc.
Luciole Pharmaceuticals, Inc. United States

Bringing Energy to Life

3 employees
Biotechnology
MitoRx Therapeutics vs
Minovia Therapeutics
Minovia Therapeutics Israel

A clinical-stage international biotechnology research company focused on treatment innovation for mi...

28 employees
MitoRx Therapeutics vs
Sulfateq B.V.
Sulfateq B.V.

Empowering Health

7 employees
Biotechnology, Health Care

FAQ About MitoRx Therapeutics

Developing new treatments to restore healthy mitochondrial metabolism in patients living with high-risk obesity.
MitoRx Therapeutics was founded in 2021.
MitoRx Therapeutics is headquartered in Oxford, United Kingdom.
MitoRx Therapeutics operates in the following industries: Biotechnology, Health and Wellness.
MitoRx Therapeutics has approximately 17 employees.
MitoRx Therapeutics has completed 3 funding rounds, raising a total of $4.00M. The latest funding stage is Seed.
MitoRx Therapeutics offers: development of obesity treatments, restoration of mitochondrial metabolism, therapy for insulin resistance.
Top alternatives and competitors to MitoRx Therapeutics include Luciole Pharmaceuticals, Inc., Minovia Therapeutics , Sulfateq B.V., RiboNova, Inc., OMEICOS Therapeutics GmbH. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MitoRx Therapeutics and Luciole Pharmaceuticals, Inc. are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors MitoRx Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy